Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.

ADP is a key agonist in hemostasis and thrombosis. ADP-induced platelet activation involves the purinergic P2Y(1) receptor, which is responsible for shape change through intracellular calcium mobilization. This process also depends on an unidentified P2 receptor (P2cyc) that leads to adenylyl cyclase inhibition and promotes the completion and amplification of the platelet response. P2Y(1)-null mice were generated to define the role of the P2Y(1) receptor and to determine whether the unidentified P2cyc receptor is distinct from P2Y(1). These mice are viable with no apparent abnormalities affecting their development, survival, reproduction, or the morphology of their platelets, and the platelet count in these animals is identical to that of wild-type mice. However, platelets from P2Y(1)-deficient mice are unable to aggregate in response to usual concentrations of ADP and display impaired aggregation to other agonists, while high concentrations of ADP induce platelet aggregation without shape change. In addition, ADP-induced inhibition of adenylyl cyclase still occurs, demonstrating the existence of an ADP receptor distinct from P2Y(1). P2Y(1)-null mice have no spontaneous bleeding tendency but are resistant to thromboembolism induced by intravenous injection of ADP or collagen and adrenaline. Hence, the P2Y(1) receptor plays an essential role in thrombotic states and represents a potential target for antithrombotic drugs.

[1]  M. Silver,et al.  Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. , 1983, The Journal of pharmacology and experimental therapeutics.

[2]  U. Walter,et al.  Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. , 1998, European journal of pharmacology.

[3]  E. M. Jones,et al.  Cloning of rat and mouse P2Y purinoceptors. , 1995, Biochemical and biophysical research communications.

[4]  J. Kimura,et al.  No requirement of P2X1 purinoceptors for platelet aggregation. , 1999, European journal of pharmacology.

[5]  J. Cazenave,et al.  Presence of P2X1 Purinoceptors in Human Platelets and Megakaryoblastic Cell Lines , 1997, Thrombosis and Haemostasis.

[6]  A. Mackenzie,et al.  Activation of Receptor-operated Cation Channels via P Not P Purinoceptors in Human Platelets (*) , 1996, The Journal of Biological Chemistry.

[7]  P. Ohlmann,et al.  The P2Y1 Receptor Is Normal in a Patient Presenting a Severe Deficiency of ADP-induced Platelet Aggregation , 1999, Thrombosis and Haemostasis.

[8]  S. Watson,et al.  Collagen receptor signalling in platelets: extending the role of the ITAM. , 1998, Immunology today.

[9]  S. Kunapuli,et al.  Molecular Basis for ADP-induced Platelet Activation , 1998, The Journal of Biological Chemistry.

[10]  J. Neary,et al.  The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase , 1996, British journal of pharmacology.

[11]  B. Ashby,et al.  Molecular Basis for ADP-induced Platelet Activation , 1998, The Journal of Biological Chemistry.

[12]  P. Conley,et al.  Evidence for Two Distinct G-protein-coupled ADP Receptors Mediating Platelet Activation , 1999, Thrombosis and Haemostasis.

[13]  T. K. Harden,et al.  Identification of competitive antagonists of the P2Y1 receptor. , 1996, Molecular pharmacology.

[14]  G. Dubyak,et al.  The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. , 1998, Blood.

[15]  P. Leff,et al.  FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T‐purinoceptors , 1994, British journal of pharmacology.

[16]  M. Kaghad,et al.  Role of P2Y1 purinoceptor in ADP‐induced platelet activation , 1998, FEBS letters.

[17]  J. Cazenave,et al.  The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. , 1998, Blood.

[18]  M. Leon,et al.  Restenosis after coronary angioplasty. , 1997, Current problems in cardiology.

[19]  Jess Li,et al.  P2X1 Purinoceptor in Human Platelets , 1998, The Journal of Biological Chemistry.

[20]  D. Mills,et al.  ADP Receptors on Platelets , 1996, Thrombosis and Haemostasis.

[21]  M. Moroi.  [Platelet receptors for collagen]. , 2000, Seikagaku. The Journal of Japanese Biochemical Society.

[22]  M. Heath,et al.  Identification of a P2X1 purinoceptor expressed on human platelets. , 1998, Biochemical and biophysical research communications.

[23]  D. Candinas,et al.  Loss of ATP Diphosphohydrolase Activity with Endothelial Cell Activation , 1997, The Journal of experimental medicine.

[24]  Brian Savage,et al.  Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow , 1998, Cell.

[25]  Patricia D. Christie,et al.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.

[26]  K. Patel,et al.  Selective expression of purinoceptor cP2Y1 suggests a role for nucleotide signalling in development of the chick embryo , 1999, Developmental dynamics : an official publication of the American Association of Anatomists.

[27]  P. Chambon,et al.  Disruption of the Hox-1.6 homeobox gene results in defects in a region corresponding to its rostral domain of expression , 1991, Cell.

[28]  P. Nurden,et al.  An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. , 1995, The Journal of clinical investigation.

[29]  S. Kunapuli,et al.  Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Cazenave,et al.  Epinephrine potentiates human platelet activation but is not an aggregating agent. , 1988, The American journal of physiology.

[31]  M. J. Robertson,et al.  P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptors , 1998, British journal of pharmacology.

[32]  C. Gachet,et al.  ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. , 1998, Molecular pharmacology.

[33]  G. Burnstock,et al.  Cloning and functional expression of a brain G‐protein‐coupled ATP receptor , 1993, FEBS letters.

[34]  J. Cazenave,et al.  The P2Y1 receptor, necessary but not sufficient to support full ADP‐induced platelet aggregation, is not the target of the drug clopidogrel , 1998, British journal of haematology.

[35]  A. Hellem,et al.  Adenosine Diphosphate in Red Cells as a Factor in the Adhesiveness of Human Blood Platelets , 1961, Nature.

[36]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.

[37]  U. Walter,et al.  Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Cazenave,et al.  The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells , 1997, FEBS letters.

[39]  B. Nürnberg,et al.  The human platelet ADP receptor activates Gi2 proteins. , 1995, The Biochemical journal.

[40]  M. Hurle,et al.  Selective Inhibition of A Fibril Formation , 1996, The Journal of Biological Chemistry.

[41]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.